A rep has a few minutes with a doctor. If every brand in the country plan is a priority, the rep decides which one leads the call. Different reps decide differently, and the strategy ends up being written in the clinic corridor, one call at a time.
With this edition the ladder moves to the country manager. Season 3 is about setting the direction the whole country follows, and the first test of that direction is whether it changes what happens in a doctor's room.
Step 1 of the Pharma Career Ladder for country managers is setting strategy.
Start with what you leave out
Weak country plans list every brand as a priority. Michael Porter wrote that the essence of strategy is choosing what not to do, and that idea is easier to quote than to live by. Choosing means a few brands get most of the time and budget, and the rest are maintained, openly. The segments you won't chase this year are named. Every rep knows which brand leads every call. When headquarters asks for growth, your answer includes what you'll stop, and why.
Most annual plans start from last year's sales, a growth figure and a budget split in proportion. That produces a forecast and leaves the choices unmade. Lafley and Martin's Playing to Win describes strategy as a set of linked choices, and 2 of them come before any number goes on a slide: where will we play, and how will we win there? If the team can't say in plain words why a doctor, a pharmacist or a hospital would choose you over what they already use, the plan is hoping. In my teams this conversation takes longer than the budget, and saves time later.
Then check where the people and the money really go. 4 things show the real strategy: rep time by brand, the promotion budget, the first brand in the call, and which brands fill leadership meetings. Once a quarter, put them next to the brand plan. Where they disagree, move the resource or change the plan. Either is honest. Leaving the gap isn't.
Read the portfolio honestly
Few leadership teams will say out loud which brands pay for the plan and which only consume it. The BCG growth-share matrix is decades old and still one of the most useful hours a country team can spend. Stars get investment to hold the lead. Cash cows are protected, because they fund everything else. Question marks are backed properly or stepped back from, since half-backing is the expensive option. Dogs stay lean or get an exit plan. Place each brand by where its segment is going, and judge share on sell-out and market data. Sell-in only tells you what the distributor bought. The matrix is easy. Being honest about your favourite brand is not.
When growth is needed, the talk often jumps to the next launch. Ansoff's growth matrix is a useful brake: 4 routes to growth, with risk rising at each step, from existing brands with existing customers out to new brands for new customers. The first route gets skipped because it sounds ordinary. Before signing off the fourth, ask what's still left in the first.
Then there's the brand that should be stopped. Ask the field first, check which patients still depend on it, and bring in medical and regulatory early for supply continuity and any notice the authority needs. Stop sell-in in time so distributor inventory runs down cleanly, never with a last large order into the trade. Tell doctors and pharmacists properly, with a clear date, and move the freed time to brands that can grow.
Choose where you compete
Most country plans spend pages on the competitor. Porter's five forces asks a wider question: what decides how much a market lets you earn? In a Gulf pharma market each force has a familiar face. Buyers like tender committees, insurers and pharmacy chains shape your net price. A single plant with long lead times is a supplier risk. Registration slows new generics without stopping them. Margin is usually lost to a tender, a formulary decision or a supply gap nobody put on the agenda. Once a year, map all 5 for each key brand with the whole leadership team.
When choosing a therapy area, climb from the bottom: is the need real, does it fit your strongest prescribers and channels, can you build the capability, and do you have a right to win? A growing market is an invitation. A right to win is a reason.
The same discipline applies to in-licensing decisions. Before any term sheet, ask whether you can register it, whether the margin works at the public price the authority is likely to set, who must say yes before a doctor can prescribe, and what minimums the partner expects. Bring medical, regulatory, finance and supply in early.
Make it usable in the field
Ask 5 reps what a brand stands for and you often get 5 answers. Ries and Trout wrote that positioning is what you do to the mind of the customer. I ask for positioning in one sentence: 1 type of patient, 1 chosen strength, and the proof, with every claim inside the label. Can a rep say it in one breath? Can a doctor repeat it after the call?
A doctor list split into A, B and C is targeting, a rep-level decision. Segmentation above the rep asks which patients the brand helps, which channel, what access the patient has through formulary, tender, insurance or self-pay, and what the prescriber's mindset is. Reps choose doctors. Leaders choose segments.
Then avoid the plan nobody reads. A usable brand plan is 1 page a first-line manager can explain without notes, with 3 priorities, the target segments and 1 core message. Open it at every cycle meeting.
Keep it alive
Watch for the black horse, the brand with little field time that keeps growing on sell-out. Ask pharmacists and the doctors who use it why it moves, let medical review the evidence and finance check the margin, then make a small bet.
When a brand keeps missing, check whether the strategy ever landed before you replace it. Find where it stalls on sell-out, go on double visits to hear the call as the doctor hears it, and name the gap. Right doctors with the wrong words is a message problem. Right words with too few of the right doctors is an execution problem. Fix 1 thing, then watch.
When a competitor moves, resist the emergency campaign and the extra stock pushed into the distributor. A planned competitive response reads what they actually did, keeps the agreed bonus terms, re-briefs managers on the segments at risk and changes only the exposed tactics. Never talk down their product. Talk about your own evidence.
Finally, set a strategy review cadence. Weekly, sell-out and distributor inventory. Monthly, execution. Quarterly, the strategy itself. Yearly, the big choices. Watch the numbers weekly. Question the strategy quarterly.
Your checklist for this week
- Write down 3 things your plan will stop or maintain this year
- Ask 3 reps which brand leads their calls, and compare the answers
- Put rep time, promotion budget, first brand in the call and leadership time next to the brand plan
- Place every brand in the growth-share boxes using sell-out and market data
- Map the 5 forces for your biggest brand with the leadership team
- Test your lead brand's positioning: can a rep say it in one breath?
- Cut your brand plan to 1 page a first-line manager can explain
- Set your weekly, monthly, quarterly and yearly review agenda
That's Step 1. Next week Step 2 begins: launches and the portfolio, starting with why the order of a launch matters more than its speed.